Eli Lilly Disputes New York Times Report

Law360, New York (December 18, 2006, 12:00 AM EST) -- Eli Lilly & Co. downplayed the risks of its schizophrenia and bipolar disorder drug Zyprexa while also encouraging doctors to prescribe the drug for patients that had neither condition, according to company marketing documents.

A lawyer for patients gave the documents to the New York Times. The newspaper said that Lilly executives kept important information from doctors about Zyprexa’s ties to obesity and its tendency to raise blood sugar, both of which cause diabetes.

The Times said that Lilly’s published data has shown that 30% of...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.